| S7588 |
Reversine
|
Reversine is a potent human A3 adenosine receptor antagonist with Ki of 0.66 μM, and a pan-aurora A/B/C kinase inhibitor with IC50 of 400 nM/500 nM/400 nM, respectively. Also used for stem cell dedifferentiation.
|
-
Nat Cell Biol, 2025, 27(1):59-72
-
EMBO J, 2024, 43(19):4324-4355
-
Sci Adv, 2024, 10(44):eado6607
|
|
| S2153 |
CGS 21680 HCl
|
CGS 21680 HCl is an adenosine A2 receptor agonist with an IC50 of 22 nM, exhibiting 140-fold over A1 receptor.
|
-
Clin Immunol, 2024, 266:110309
-
CNS Neurosci Ther, 2024, 30(5):e14726
-
Cell Rep Med, 2023, 4(9):101188
|
|
| S1647 |
Adenosine
|
Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ">-"N9-glycosidic bond.
|
-
Cancer Cell, 2025, 43(4):776-796.e14
-
J Infect, 2025, 90(4):106449
-
Nat Commun, 2025, 16(1):10378
|
|
| S8105 |
ZM241385
|
ZM-241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.
|
-
Nature, 2025, 10.1038/s41586-025-09755-9
-
J Infect, 2025, 90(4):106449
-
Front Cell Dev Biol, 2022, 10:827714
|
|
| S2790 |
Istradefylline
|
Istradefylline (KW-6002) is a selective adenosine A2A receptor (A2AR) antagonist with Ki of 2.2 nM. Phase 3.
|
-
J Infect, 2025, 90(4):106449
-
Sci Adv, 2025, 11(9):eadq1724
-
Nat Commun, 2023, 14(1):3364
|
|
| S8104 |
SCH58261
|
SCH 58261 is a potent and selective A2a adenosine receptor antagonist with Ki of 2.3 nM and 2 nM for rat A2a and bovine A2a, respectively.
|
-
CNS Neurosci Ther, 2024, 30(5):e14726
-
Molecules, 2022, 27(19)6267
-
J Neurochem, 2021, 10.1111/jnc.15436
|
|
| S9608 |
Etrumadenant (AB928)
|
Etrumadenant (AB928, A2aR/A2bR antagonist-1) is a novel dual A2aR/A2bR antagonist, with Kd values of 1.4 nM and 2 nM for A2aR and A2bR, respectively.
|
-
FEBS Open Bio, 2025, 15(2):335-345
-
Nat Prod Commun, 2022, 17(10): 1–8
-
Natural Product Communications, 2022, 2022;17(10)
|
|
| S8575 |
A2AR antagonist 1
|
A2AR antagonist 1 is a potent A2AR (Adenosine A2A Receptor) antagonist with Ki values of 4 nM and 264 nM for A2AR and A1R, respectively.
|
-
MedComm (2020), 2023, 4(2):e242
-
Mol Cancer Res, 2019, 17(5):1166-1179
|
|
| S6646 |
Ciforadenant (CPI-444)
|
Ciforadenant (CPI-444, V81444) is a potent and selective Adenosine A2A receptor antagonist. It binds to A2A receptors with a Ki of 3.54 nmol/L and demonstrates greater than 50-fold selectivity for the A2A receptor over other adenosine receptor subtypes.
|
-
Cancer Immunol Immunother, 2024, 73(6):108
-
Cell Mol Gastroenterol Hepatol, 2022, S2352-345X(22)00163-1
|
|
| E1310 |
DPCPX
|
DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective adenosine A1 receptor (ADORA1) antagonist, with a Ki of 0.46 nM.
|
-
Cell Biol Toxicol, 2024, 40(1):59
|
|